You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Reyes R, Deng Y, Zhang D, et al
719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0719